{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:26:14Z","timestamp":1770895574370,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 and DTT-304 that both selectively enrich in the lysosomal compartment of cancer cells yet differ to some extent in their cytotoxic mode of action. While DTT-304 can trigger the aggregation of RIP3 in ripoptosomes, coupled to the phosphorylation of MLKL by RIP3, DTT-205 fails to activate RIP3. Accordingly, knockout of either RIP3 or MLKL caused partial resistance against cell killing by DTT-304 but not DTT-205. In contrast, both agents shared common features in other aspects of pro-death signaling in the sense that their cytotoxic effects were strongly inhibited by both serum and antioxidants, partially reduced by lysosomal inhibition with bafilomycin A1 or double knockout of Bax and Bak, yet totally refractory to caspase inhibition. Both DTT-304 and DTT-205 caused the exposure of calreticulin at the cell surface, as well as the release of HMGB1 from the cells. Mice bearing established subcutaneous cancers could be cured by local injection of DTT-205 or DTT-304, and this effect depended on T lymphocytes, as it led to the establishment of a long-term memory response against tumor-associated antigens. Thus, mice that had been cured from cancer by the administration of DTT compounds were refractory against rechallenge with the same cancer type several months after the disappearance of the primary lesion. In summary, DTT-205 and DTT-304 both have the capacity to induce immunotherapeutic oncolysis.<\/jats:p>","DOI":"10.1038\/s41419-018-1127-3","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T08:55:05Z","timestamp":1540284905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals"],"prefix":"10.1038","volume":"9","author":[{"given":"Heng","family":"Zhou","sequence":"first","affiliation":[]},{"given":"Laura","family":"Mondrag\u00f3n","sequence":"additional","affiliation":[]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[]},{"given":"Brynjar","family":"Mauseth","sequence":"additional","affiliation":[]},{"given":"Marion","family":"Leduc","sequence":"additional","affiliation":[]},{"given":"Allan","family":"Sauvat","sequence":"additional","affiliation":[]},{"given":"L\u00edgia C.","family":"Gomes-da-Silva","sequence":"additional","affiliation":[]},{"given":"Sabrina","family":"Forveille","sequence":"additional","affiliation":[]},{"given":"Kristina","family":"Iribarren","sequence":"additional","affiliation":[]},{"given":"Sylvie","family":"Souquere","sequence":"additional","affiliation":[]},{"given":"Lucillia","family":"Bezu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-9222","authenticated-orcid":false,"given":"Peng","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Liwei","family":"Zhao","sequence":"additional","affiliation":[]},{"given":"Laurence","family":"Zitvogel","sequence":"additional","affiliation":[]},{"given":"Baldur","family":"Sveinbj\u00f8rnsson","sequence":"additional","affiliation":[]},{"given":"J. Johannes","family":"Eksteen","sequence":"additional","affiliation":[]},{"given":"\u00d8ystein","family":"Rekdal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-9558","authenticated-orcid":false,"given":"Oliver","family":"Kepp","sequence":"additional","affiliation":[]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"1127_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1083\/jcb.200910104","volume":"188","author":"E Ruoslahti","year":"2010","unstructured":"Ruoslahti, E., Bhatia, S. N. & Sailor, M. J. Targeting of drugs and nanoparticles to tumors. J. Cell. Biol. 188, 759\u2013768 (2010).","journal-title":"J. Cell. Biol."},{"key":"1127_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.peptides.2008.12.019","volume":"30","author":"T Iwasaki","year":"2009","unstructured":"Iwasaki, T. et al. Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides 30, 660\u2013668 (2009).","journal-title":"Peptides"},{"key":"1127_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s00018-005-4560-2","volume":"62","author":"N Papo","year":"2005","unstructured":"Papo, N. & Shai, Y. Host defense peptides as new weapons in cancer treatment. Cell. Mol. Life Sci. 62, 784\u2013790 (2005).","journal-title":"Cell. Mol. Life Sci."},{"key":"1127_CR4","doi-asserted-by":"publisher","first-page":"e0148980","DOI":"10.1371\/journal.pone.0148980","volume":"11","author":"LM Eike","year":"2016","unstructured":"Eike, L. M., Mauseth, B., Camilio, K. A., Rekdal, O. & Sveinbjornsson, B. The cytolytic amphipathic beta(2,2)-amino acid LTX-401 induces DAMP release in melanoma cells and causes complete regression of B16 melanoma. PLoS. One. 11, e0148980 (2016).","journal-title":"PLoS. One."},{"key":"1127_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.4155\/fmc-2017-0088","volume":"9","author":"B Sveinbjornsson","year":"2017","unstructured":"Sveinbjornsson, B., Camilio, K. A., Haug, B. E. & Rekdal, O. LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. Future Med. Chem. 9, 1339\u20131344 (2017).","journal-title":"Future Med. Chem."},{"key":"1127_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/cdd.2016.35","volume":"23","author":"T Yamazaki","year":"2016","unstructured":"Yamazaki, T. et al. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 23, 1004\u20131015 (2016).","journal-title":"Cell Death Differ."},{"key":"1127_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.47","volume":"7","author":"H Zhou","year":"2016","unstructured":"Zhou, H. et al. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 7, e2134 (2016).","journal-title":"Cell Death Dis."},{"key":"1127_CR8","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1038\/cdd.2016.86","volume":"23","author":"H Zhou","year":"2016","unstructured":"Zhou, H. et al. The oncolytic compound LTX-401 targets the Golgi apparatus. Cell Death Differ. 23, 2031\u20132041 (2016).","journal-title":"Cell Death Differ."},{"key":"1127_CR9","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.3390\/ijms12118027","volume":"12","author":"S Al-Benna","year":"2011","unstructured":"Al-Benna, S., Shai, Y., Jacobsen, F. & Steinstraesser, L. Oncolytic activities of host defense peptides. Int. J. Mol. Sci. 12, 8027\u20138051 (2011).","journal-title":"Int. J. Mol. Sci."},{"key":"1127_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99\u2013163 (2007).","journal-title":"Physiol. Rev."},{"key":"1127_CR11","doi-asserted-by":"crossref","first-page":"26599","DOI":"10.18632\/oncotarget.5613","volume":"6","author":"H Zhou","year":"2015","unstructured":"Zhou, H. et al. The oncolytic peptide LTX-315 kills cancer cells through Bax\/Bak-regulated mitochondrial membrane permeabilization. Oncotarget 6, 26599\u201326614 (2015).","journal-title":"Oncotarget"},{"key":"1127_CR12","doi-asserted-by":"publisher","first-page":"34910","DOI":"10.18632\/oncotarget.5308","volume":"6","author":"LM Eike","year":"2015","unstructured":"Eike, L. M., Yang, N., Rekdal, O. & Sveinbjornsson, B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget 6, 34910\u201334923 (2015).","journal-title":"Oncotarget"},{"key":"1127_CR13","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1080\/15384101.2016.1160609","volume":"15","author":"A Sistigu","year":"2016","unstructured":"Sistigu, A., Manic, G. & Vitale, I. LTX-315, CAPtivating immunity with necrosis. Cell Cycle 15, 1176\u20131177 (2016).","journal-title":"Cell Cycle"},{"key":"1127_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1127_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/imr.12582","volume":"280","author":"N Bloy","year":"2017","unstructured":"Bloy, N. et al. Immunogenic stress and death of cancer cells: contribution of antigenicity vs adjuvanticity to immunosurveillance. Immunol. Rev. 280, 165\u2013174 (2017).","journal-title":"Immunol. Rev."},{"key":"1127_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313\u2013322 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"1127_CR17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 28, 690\u2013714 (2015).","journal-title":"Cancer Cell."},{"key":"1127_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1127_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54\u201361 (2007).","journal-title":"Nat. Med."},{"key":"1127_CR20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059 (2007).","journal-title":"Nat. Med."},{"key":"1127_CR21","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/nm.2028","volume":"15","author":"F Ghiringhelli","year":"2009","unstructured":"Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170\u20131178 (2009).","journal-title":"Nat. Med."},{"key":"1127_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00262-014-1540-0","volume":"63","author":"KA Camilio","year":"2014","unstructured":"Camilio, K. A., Berge, G., Ravuri, C. S., Rekdal, O. & Sveinbjornsson, B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol. Immunother. 63, 601\u2013613 (2014).","journal-title":"Cancer Immunol. Immunother."},{"key":"1127_CR23","doi-asserted-by":"publisher","first-page":"e29181","DOI":"10.4161\/onci.29181","volume":"3","author":"KA Camilio","year":"2014","unstructured":"Camilio, K. A., Rekdal, O. & Sveinbjornsson, B. LTX-315 (oncopore): a short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology 3, e29181 (2014).","journal-title":"Oncoimmunology"},{"key":"1127_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1021\/acs.jmedchem.6b00839","volume":"60","author":"JJ Eksteen","year":"2017","unstructured":"Eksteen, J. J. et al. Iterative design and in vivo evaluation of an oncolytic antilymphoma peptide. J. Med. Chem. 60, 146\u2013156 (2017).","journal-title":"J. Med. Chem."},{"key":"1127_CR25","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1080\/15384101.2015.1093710","volume":"14","author":"S Forveille","year":"2015","unstructured":"Forveille, S. et al. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle 14, 3506\u20133512 (2015).","journal-title":"Cell Cycle"},{"key":"1127_CR26","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1242\/jcs.091181","volume":"126","author":"S Aits","year":"2013","unstructured":"Aits, S. & Jaattela, M. Lysosomal cell death at a glance. J. Cell. Sci. 126, 1905\u20131912 (2013).","journal-title":"J. Cell. Sci."},{"key":"1127_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.immuni.2016.01.020","volume":"44","author":"L Galluzzi","year":"2016","unstructured":"Galluzzi, L., Lopez-Soto, A., Kumar, S. & Kroemer, G. Caspases connect cell-death signaling to organismal homeostasis. Immunity 44, 221\u2013231 (2016).","journal-title":"Immunity"},{"key":"1127_CR28","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.cell.2009.05.037","volume":"137","author":"YS Cho","year":"2009","unstructured":"Cho, Y. S. et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137, 1112\u20131123 (2009).","journal-title":"Cell"},{"key":"1127_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1310050","volume":"370","author":"A Linkermann","year":"2014","unstructured":"Linkermann, A. & Green, D. R. Necroptosis. N. Engl. J. Med. 370, 455\u2013465 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1127_CR30","doi-asserted-by":"publisher","first-page":"e1149673","DOI":"10.1080\/2162402X.2016.1149673","volume":"5","author":"H Yang","year":"2016","unstructured":"Yang, H. et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology 5, e1149673 (2016).","journal-title":"Oncoimmunology"},{"key":"1127_CR31","doi-asserted-by":"publisher","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","volume":"28","author":"A Marabelle","year":"2017","unstructured":"Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28, xii33\u2013xii43 (2017).","journal-title":"Ann. Oncol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1127-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1127-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T14:58:14Z","timestamp":1672671494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-1127-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["1127"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-1127-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"4 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1086"}}